Dr. Katie Murray discusses the diagnosis and management of non–muscle invasive bladder cancer, emphasizing cystoscopy and initial TURBT as the standard for accurate diagnosis and pathology. She notes that low-grade bladder cancer has a high recurrence rate, often within the first year. Traditionally, recurrences required repeat surgery, but newer FDA-approved intravesical chemoablative therapies now offer an alternative. These options may help some patients avoid returning to the operating room while effectively treating recurrent disease.
